Aug 5 - Pfizer (NYSE:PFE) heads into its Q2 earnings release amid growing investor caution. Analysts expect revenue around ...

Pfizer beats Q2 2025 estimates, raises EPS guidance, boasts a 7%+ dividend yield, yet faces patent and pricing risks. See why ...

PFE posts strong Q2 results with earnings up 30% and revenues up 10% year over year, fueled by rising oncology sales and cost ...

Pharmaceutical major recorded a revenue jump to $14.65 billion, exceeding the market expectations. The company also raised ...

Pfizer (NYSE:PFE) stock gains as the company surpasses Q2 2025 expectations with $14.7B revenue and raises its full-year ...

Pfizer, the U.S.-based pharmaceutical giant, revealed its second-quarter financial results on Tuesday, showcasing a robust 10 ...

Aug 5 - Pfizer (NYSE:PFE) heads into its Q2 earnings release amid growing investor caution. Analysts expect revenue around ...

Pfizer (PFE) stock is rising after the company reported strong second-quarter earnings and lifted its full-year forecast ...

Pfizer (PFE) stock is moving higher after beating Wall Street expectations for the second quarter and raising its full-year ...

Pfizer Inc. (NYSE:PFE) will release earnings results for the second quarter before the opening bell on Tuesday, Aug. 5.

Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

Pfizer stock rises after a strong Q2, boosted by cost savings, pipeline progress, and an upgraded 2025 profit outlook.